Wedbush Reaffirms Neutral Rating for Nuvalent (NASDAQ:NUVL)

Nuvalent (NASDAQ:NUVL)‘s stock had its “neutral” rating restated by investment analysts at Wedbush in a research report issued on Tuesday,Benzinga reports. They currently have a $124.00 target price on the stock, down from their previous target price of $125.00. Wedbush’s price objective would indicate a potential upside of 0.92% from the stock’s previous close.

Several other research firms have also issued reports on NUVL. HC Wainwright reissued a “buy” rating and issued a $155.00 price target on shares of Nuvalent in a research report on Tuesday, April 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Nuvalent in a research report on Tuesday, June 2nd. Sanford C. Bernstein assumed coverage on shares of Nuvalent in a research note on Thursday, May 21st. They issued an “outperform” rating and a $189.00 target price for the company. Finally, Leerink Partners set a $165.00 price target on shares of Nuvalent in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $140.22.

Nuvalent Price Performance

Shares of Nuvalent stock opened at $122.87 on Tuesday. The firm has a market cap of $9.71 billion, a price-to-earnings ratio of -20.28 and a beta of 1.15. The stock has a 50-day simple moving average of $102.38 and a 200-day simple moving average of $102.97. Nuvalent has a 52-week low of $71.13 and a 52-week high of $122.83.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the previous year, the business posted ($1.18) EPS. As a group, equities research analysts predict that Nuvalent will post -5.74 earnings per share for the current year.

Insider Transactions at Nuvalent

In other news, CEO James Richard Porter sold 30,000 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the transaction, the chief executive officer directly owned 324,879 shares in the company, valued at $33,036,945.51. This represents a 8.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Alexandra Balcom sold 11,430 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total value of $1,202,550.30. Following the completion of the transaction, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,998,926.93. This represents a 11.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 96,953 shares of company stock worth $9,956,364. Insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Several hedge funds have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC increased its position in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after acquiring an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Nuvalent during the third quarter valued at approximately $38,000. NBC Securities Inc. acquired a new position in shares of Nuvalent during the fourth quarter worth approximately $125,000. Finally, KBC Group NV lifted its holdings in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after purchasing an additional 297 shares in the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK agreed to buy Nuvalent for $10.6 billion, giving NUVL shareholders a large acquisition premium and effectively taking the company private. Reuters: UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
• Positive Sentiment: The deal validates Nuvalent’s oncology assets, including experimental lung cancer therapies that have attracted enough interest to prompt a major strategic acquisition. WSJ: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
• Neutral Sentiment: Several reports noted that the deal is part of GSK’s push to strengthen its oncology pipeline and offset future patent pressure elsewhere in its business. Proactive Investors: GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
• Neutral Sentiment: Some market commentary suggested investors were more focused on GSK’s valuation impact than on Nuvalent itself, but the transaction still confirms the stock’s upside is now tied to deal completion. Invezz: GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.